BRIEF—Alnylam announces planned CEO transition

Shares of USA-based RNA interference (RNAi) specialist Alnylam Pharmaceuticals plunged more than 14% to $168.98 today as the company revealed that its long-time chief executive was leaving the company.

Alnylam announced today the planned CEO transition of John Maraganore, to Yvonne Greenstreet, at year-end 2021.

Dr Maraganore joined Alnylam in 2002 as the company’s founding CEO and has led the company’s advancement of RNAi therapeutics as a whole new class of innovative medicines, including four approved medicines marketed in over 25 countries around the world.

Dr Greenstreet joined Alnylam in 2016 and currently serves as the company’s president and chief operating officer.

Dr Maraganore will support the leadership transition in a consulting capacity through March 31, 2022 and will continue to contribute to Alnylam’s success as a member of the company’s scientific advisory board.

Effective immediately, Dr Greenstreet has been appointed to the Alnylam board of directors as part of the planned succession.